SEARCH

SEARCH BY CITATION

References

  • 1
    Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 10671079.
  • 2
    Nelson RL. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; CD004610. doi: 10.1002/14651858.CD004610.pub4.
  • 3
    Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431455.
  • 4
    Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478498.
  • 5
    Cheng AC, Ferguson JK, Richards MJ et al. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust 2011; 194: 353358.
  • 6
    Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 26: 924926.
  • 7
    Hsu J, Brożek JL, Terracciano L et al. Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines. Implement Sci 2011; 6: 62.
  • 8
    Ullmann AJ, Cornely OA, Donnelly JP et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 2012; 18: 18.
  • 9
    Brouwers MC, Kho ME, Browman GP et al. AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 2010; 51: 421424.
  • 10
    Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46 (suppl 1): S12S18.
  • 11
    Kuijper EJE, Coignard BB, Tüll PP. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (suppl 6): 218.
  • 12
    Crobach MJT, Goorhuis A, Kelly CP et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15: 10531066.
  • 13
    Wilcox MH, Planche T, Fang FC. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol 2010; 48: 43474353.
  • 14
    Davies KA, Planche TD, Coen P et al. The largest ever study to define a testing algorithm to optimize the laboratory diagnosis of C. difficile infection. In: 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2012 in London, UK. Abstract LB2817.
  • 15
    Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 2013; 13: 936945.
  • 16
    O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439440.
  • 17
    McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140145.
  • 18
    Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920924.
  • 19
    Knoop FC, Owens M, Crocker IC. Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev 1993; 6: 251265.
  • 20
    Moudgal V, Sobel J. Clostridium difficile colitis: a review. Hosp Pract 2012; 40: 139148.
  • 21
    Kuijper EJ, Wilcox MH. Editorial commentary: decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008; 47: 6365.
  • 22
    Nassir Al WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RLP, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 5662.
  • 23
    Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36: 673679.
  • 24
    Louie TJ, Peppe J, Watt CK et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 411420.
  • 25
    Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012; 18 (suppl 6): 2127.
  • 26
    Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24: 324333.
  • 27
    Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42: 758764.
  • 28
    Figueroa I, Johnson S, Sambol SP, Goldstein EJC, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012; 55 (suppl 2): S104S109.
  • 29
    Sailhamer EA, Carson K, Chang Y et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009; 144: 433439.
  • 30
    Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg 2008; 196: 384388.
  • 31
    Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363372.
  • 32
    Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009; 15: 415422.
  • 33
    Kelly MCP, LaMont MJT. Clostridium difficile infection. Annu Rev Med 1998; 49: 375390.
  • 34
    Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350354.
  • 35
    Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004; 47: 16201626.
  • 36
    Miller MA, Louie T, Mullane K et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis 2013; 13: 148.
  • 37
    Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG. CSI: a severity index for Clostridium difficile infection at the time of admission. J Hosp Infect 2011; 79: 151154.
  • 38
    Morgan OW, Rodrigues B, Elston T et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case–case study. PLoS ONE 2008; 3: e1812.
  • 39
    Huttunen R, Vuento R, Syrjänen J, Tissari P, Aittoniemi J. Case fatality associated with a hypervirulent strain in patients with culture-positive Clostridium difficile infection: a retrospective population-based study. Int J Infect Dis 2012; 16: e532e535.
  • 40
    Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 (suppl 2): S93S103.
  • 41
    Welfare MR, Welfare MR, Lalayiannis LC et al. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011; 79: 359363.
  • 42
    Hu MY, Katchar K, Kyne L et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136: 12061214.
  • 43
    Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70: 298304.
  • 44
    Voelker R. Increased Clostridium difficile virulence demands new treatment approach. JAMA 2010; 26: 20172019.
  • 45
    Bauer MP, Hensgens MPM, Miller MA et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis 2012; 55 (suppl 2): S149S153.
  • 46
    Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS ONE 2012; 7: e30258.
  • 47
    Miller M, Gravel D, Mulvey M et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50: 194201.
  • 48
    Walk ST, Micic D, Jain R et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012; 55: 16611668.
  • 49
    Walker AS, Eyre DW, Crook DW, Peto TE, Wilcox MH. Response to Walk et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2013; 56: 15891600.
  • 50
    Walker AS, Eyre DW, Wyllie DH et al. Relationship between bacterial strain type, host biomarkers and mortality in Clostridium difficile infection. Clin Infect Dis 2013; 56: 15891600.
  • 51
    Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47: 11621170.
  • 52
    Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011; 60: 10701079.
  • 53
    Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. Mouse relapse model of Clostridium difficile infection. Infect Immun 2011; 79: 28562864.
  • 54
    Wullt M, Noren T, Ljungh A, Akerlund T. IgG antibody response to toxins A and B in patients with Clostridium difficile infection. Clin Vaccine Immunol 2012; 19: 15521554.
  • 55
    Wilcox M, Minton J. Role of antibody response in outcome of antibiotic-associated diarrhoea. Lancet 2001; 357: 158159.
  • 56
    Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 53: 882884.
  • 57
    Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189193.
  • 58
    Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390397.
  • 59
    Warny M, Vaerman JP, Avesani V, Delmée M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384389.
  • 60
    Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13: 97101.
  • 61
    Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28: 965969.
  • 62
    Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993; 16 (suppl 4): S239S244.
  • 63
    Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 2008; 143: 623629.
  • 64
    Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002; 34: 1585.
  • 65
    Ramaswamy R, Grover H, Corpuz M, Daniels P, Pitchumoni CS. Prognostic criteria in Clostridium difficile colitis. Am J Gastroenterol 1996; 91: 460464.
  • 66
    Wenisch JM, Schmid D, Kuo HW et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis 2012; 31: 19231930.
  • 67
    Eyre DW, Walker AS, Wyllie D et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55 (suppl 2): S77S87.
  • 68
    Pépin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 15911597.
  • 69
    McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002 Jun 25; 97: 17691775.
    Direct Link:
  • 70
    Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422431.
  • 71
    Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197205.
  • 72
    Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107: 10011010.
  • 73
    Vonberg RP, Kuijper EJ, Wilcox MH et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14(suppl 5): 220.
  • 74
    Martinez FJ, Leffler DA, Kelly CP. Clostridium difficile outbreaks: prevention and treatment strategies. Risk Manag Healthc Policy 2012; 5: 5564.
  • 75
    Drekonja DM, Butler M, MacDonald R et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155: 839847.
  • 76
    Keighley MR, Burdon DW, Arabi Y et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 1978; 2: 16671669.
  • 77
    Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2: 10431046.
  • 78
    Young GP, Ward PB, Bayley N et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985; 89: 1038.
  • 79
    Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med 1986; 146: 11011104.
  • 80
    Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 1519.
  • 81
    Boero M, Berti E, Morgando A, Verme G. Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina. [Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximine vs. vancomycin]. Microbiol Med 1990; 5: 7477.
  • 82
    De Lalla F, Nicolin R, Rinaldi E et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36: 21922196.
  • 83
    The Swedish CDAD Study Group. Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. Scand J Infect Dis 1994; 26: 309316.
  • 84
    Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813818.
  • 85
    Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004; 54: 211216.
  • 86
    Musher DM, Logan N, Hamill RJ et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43: 421427.
  • 87
    Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2007; 43: 547552.
  • 88
    Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302307.
  • 89
    Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2008; 53: 223228.
  • 90
    Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48: e41e46.
  • 91
    Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281289.
  • 92
    Johnson S, Gerding D, Davidson D et al. Efficacy and safety of oral vancomycin versus oral metronidazole for treatment of Clostridium difficile- associated diarrhea (CDAD): pooled results from two randomized clinical trials. Poster presentation ID 2012. Available at https://idsa.confex.com/idsa/2012/webprogram/Paper35060.html
  • 93
    Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 8391.
  • 94
    Brazier JS, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48: 741742.
  • 95
    Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 10461052.
  • 96
    Moura I, Spigaglia P, Barbanti F, Mastrantonio P. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes. J Antimicrob Chemother 2013; 68: 362365.
  • 97
    Johnson S, Sanchez JL, Gerding DN. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000 Aug; 31: 625626.
  • 98
    Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46: 16471650.
  • 99
    Purdell J. Investigation of outcome in cases of Clostridium difficile infection due to isolates with reduced susceptibility to metronidazole. In: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2011 in Milan, Italy. Abstract: O499.
  • 100
    Bolton RPR, Culshaw MAM. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 11691172.
  • 101
    Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008 Jun; 24: 24032406.
  • 102
    Sethi AK, Nassir Al WN, Nerandzic MM, Donskey CJ. Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2009; 30: 1317.
  • 103
    Miller M, Bernard L, Thompson M et al. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2010; 31: 710715.
  • 104
    Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 (suppl 2): S132S142.
  • 105
    Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012; 55(suppl 2): S121S126.
  • 106
    De Lalla F, Privitera G, Rinaldi E, Ortisi G, Santoro D, Rizzardini G. Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob Agents Chemother 1989; 33: 11251127.
  • 107
    Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010; 50(suppl 1): S16S23.
  • 108
    McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. Clin Experiment Ophthalmol 2007; 35: 585586.
  • 109
    Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin–metronidazole interaction. Am J Geriatr Pharmacother 2008; 6: 3336.
  • 110
    Aradhyula S, Manian FA, Hafidh SAS, Bhutto SS, Alpert MA. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2006; 99: 518520.
  • 111
    Weiss K, Allgren RL, Sellers S. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Clin Infect Dis 2012; 55 (suppl 2): S110S115.
  • 112
    Iarikov DE, Alexander J, Nambiar S. Hypersensitivity reactions associated with fidaxomicin use. Clin Infect Dis 2013, in press.
  • 113
    Bartlett JGJ, Tedesco FJF, Shull SS, Lowe BB, Chang TT. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980; 78: 431434.
  • 114
    Silva J, Batts DH, Fekety R, Plouffe JF, Rifkin GD, Baird I. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med 1981; 71: 815822.
  • 115
    Cherry RDR, Portnoy DD, Jabbari MM, Daly DSD, Kinnear DGD, Goresky CAC. Metronidazole: an alternate therapy for antibiotic-associated colitis. Gastroenterology 1982; 82: 849851.
  • 116
    Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Clin Infect Dis 1984; 6 (suppl 1): S235S241.
  • 117
    Olson MM, Shanholtzer CJ, Lee JT, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol 1994; 15: 371381.
  • 118
    Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004; 38: 414.
  • 119
    Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 15861590.
  • 120
    Louie TJ. Treating Clostridium difficile in the future: what's coming? 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract 1774.
  • 121
    Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59: 705710.
  • 122
    Herpers BL, Vlaminckx B, Burkhardt O et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48: 17321735.
  • 123
    Rubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL. Rifaximin is effective for the treatment of Clostridium difficile associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract 2011. doi: 10.1155/2011/106978
  • 124
    Louie TJ, Gerson M, Grimard D et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 2007; Chicago, USA. Abstract K-425a.
  • 125
    Bouza E, Dryden M, Mohammed R et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Program and abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases April 19–22, 2008; Barcelona, Spain. Abstract O464.
  • 126
    McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994 Jun; 271: 19131918.
  • 127
    Mogg GA, George RH, Youngs D et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 1982; 69: 137139.
  • 128
    van Dissel JT. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005; 54: 197205.
  • 129
    Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007; 56: 888889.
  • 130
    Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011; 56: 1926.
  • 131
    Hempel S, Newberry SJ, Maher AR et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307: 19591969.
  • 132
    Johnston BC, Ma SSY, Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile associated diarrhea. Ann Intern Med 2012; 157: 878888.
  • 133
    Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008: CD004611. doi: 10.1002/14651858.CD004611.pub2
  • 134
    Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005; 41: 15591568.
  • 135
    Muñoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 16251634.
  • 136
    Besselink MGH, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651659.
  • 137
    McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009; 15: 274280.
  • 138
    Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P. West Midlands research collaborative systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99: 15011513.
  • 139
    Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant C. difficile colitis life saving? A systematic review Colorectal Dis 2013; 15: 798804.
  • 140
    Koss K, Clark MA, Sanders DSA, Morton D, Keighley MRB, Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006; 8: 149154.
  • 141
    Chan S, Kelly M, Helme S, Gossage J, Modarai B, Forshaw M. Outcomes following colectomy for Clostridium difficile colitis. Int J Surg 2009; 7: 7881.
  • 142
    Lee DY, Chung EL, Guend H, Whelan RL, Wedderburn RV, Rose KM. Predictors of mortality after emergency colectomy for Clostridium difficile colitis: an analysis of ACS-NSQIP. Ann Surg 2013. doi:10.1097/SLA.0b013e31828a8eba.
  • 143
    Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254: 423437.
  • 144
    Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 (suppl 2): S154S161.
  • 145
    van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407415.
  • 146
    Surawicz CM, Surawicz CM, McFarland LV et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 10121017.
  • 147
    Wullt M, Hagslätt M-LJ, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35: 365367.
  • 148
    Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005; 54: 905906.
  • 149
    Mattila E, Anttila V-J, Broas M et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008; 40: 702708.
  • 150
    Tedesco FJF, Gordon DD, Fortson WCW. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867868.
  • 151
    Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987; 9: 155.
  • 152
    Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846848.
  • 153
    Garey KW, Jiang Z-D, Bellard A, DuPont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009; 43: 9192.
  • 154
    Basu PP, Dinani A, Rayapudi K et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2010; 3: 221225.
  • 155
    Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2: 1519.
  • 156
    Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21: 224226.
  • 157
    Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg 1981; 47: 178183.
  • 158
    Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1: 1156.
  • 159
    Paterson DLD, Iredell JJ, Whitby MM. Putting back the bugs: bacterial treatment relieves chronic diarrhoea. Med J Aust 1994; 160: 232233.
  • 160
    Lund-Tønnesen S, Berstad A, Schreiner A, Midtvedt T. Clostridium difficile-associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen 1998; 118: 10271030.
  • 161
    Faust G, Langelier D, Haddad H, Menard DB. Treatment of recurrent pseudomembranous colitis (RPMC) with stool transplantation (ST): report of six (6) cases. 41st annual meeting of the Canadian Association of Gastroenterology in conjunction with the Canadian Association for the Study of the Liver, 2002; Montreal, Quebec, Canada: Abstract 002.
  • 162
    Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580585.
  • 163
    Jorup-Rönström C, Håkanson A, Persson AK, Midtvedt T, Norin E. Feces culture successful therapy in Clostridium difficile diarrhea. Lakartidningen 2006; 103: 36033605.
  • 164
    Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 2011; 45 (suppl): S159S167.
  • 165
    Wettstein A, Borody TJ, Leis S. Fecal bacteriotherapy: an effective treatment for relapsing symptomatic Clostridium difficile infection. 15th United European Gastroenterology Week; 2007, October 27–31, Paris, France: Abstract G-67]
  • 166
    Nieuwdorp M, van Nood E, Speelman P et al. Behandeling van recidiverende Clostridium difficile-geassocieerde diarree met een suspensie van donorfeces. Ned Tijdschr Geneeskd 2008; 152: 19271932.
  • 167
    Rubin TA, Gessert CE, Aas J. Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc 2009; 57: 2386.
  • 168
    MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009; 102: 781784.
  • 169
    Arkkila PE, Uusitalo-Seppälä R, Lehtola L, Moilanen V, Ristikankare M, Mattila EJ. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Gastroenterol 2010; 138: S5.
  • 170
    Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010; 44: 567570.
  • 171
    Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010; 8: 471473.
  • 172
    Mellow MHM, Kanatzar AA. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection – results and follow-up. J Okla State Med Assoc 2011; 104: 8991.
  • 173
    Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010; 44: 562566.
  • 174
    Garborg K, Waagsbo B, Stallemo A, Matre J, Sundy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010; 42: 857861.
  • 175
    Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46: 145.
  • 176
    Brandt RJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 10791087.
  • 177
    Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012; 172: 191193.
  • 178
    Hamilton MJ, Olson MM, Weingarden AR et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 761767.
  • 179
    Mattila E, Seppälä RU, Wuorela M et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142: 490496.
  • 180
    Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118: 633637.
  • 181
    Beales ILP. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 2002; 51: 456.
  • 182
    McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49: 640645.
  • 183
    Juang P, Skledar SJ, Zgheib NK et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007; 35: 131137.
  • 184
    Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010; 5: E1E9.
  • 185
    Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15: 285289.
  • 186
    Landy J, Al-Hassi HO, McLaughlin SD et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34: 409415.
  • 187
    Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500508.
  • 188
    Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol 2012; 5: 403420.
  • 189
    Guo BB, Harstall CC, Louie TT, van Zanten SSV, Dieleman LAL. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35: 865875.
  • 190
    Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 9941002.
  • 191
    Van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill 2009; 14: pii.
  • 192
    Friedenberg F, Fernandez A, Kaul V, Niami P, Levine GM. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44: 11761180.
  • 193
    McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005; 54: 101111.
  • 194
    Musgrave CR, Bookstaver PB, Sutton SS, Miller AD. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011; 15: e438e448.
  • 195
    Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother 2011; 45: 10051010.